Perforin is responsible for creating a channel/pore (punching a hole) between cytolytic lymphocytes, natural killer cells and CD8 T cells, and their target cells, allowing for the delivery of apoptosis-inducing granzyme proteins. buff.ly/YFitped #hemesky
#ASH25 Among patients with #ChronicLymphocyticLeukemia, fixed-duration targeted treatment using venetoclax-based combinations was found to achieve efficacy comparable to #BTKi therapy, with 3-year PFS ranging from 79% to 81% across all treatment arms: https://ow.ly/LOkJ50XExRg
#HemeSky #OncSky
Immune alterations in myeloma evolution and outcomes: quo vadis? buff.ly/6ft0xTG #hemesky
Excellent Review!!
Antibiotic use: impact on the microbiome and cellular therapy outcomes
buff.ly/Awz7wZU #hemesky
ASH Clinical News
No doubts #EHA is the best congress of hematology ever.
In-vivo B-cell maturation antigen CAR T-cell therapy for relapsed or refractory multiple myeloma - The Lancet www.thelancet.com/journals/lan...
In this 60-Second Journal Club, NEJM Editorial Fellow Abarna Pearl, MD, MPH, summarizes the BALANCE trial comparing antibiotic treatment for 7 versus 14 days in patients with bloodstream infections. Read the full article and accompanying Research Summary: nej.md/3Z5bTJD
#MedSky #IDSky
A rare T-cell lymphoma after chimeric antigen receptor (CAR) T-cell therapy for myeloma was linked to CCR4 overexpression and vector integration, which highlights the need for monitoring after CAR T-cell therapy. Read the full case details: nej.md/41fYX4v
#MedSky #Hematology #Genetics
